This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Michael S. Korenfeld, MD
University of Missouri-Columbia

JAMA. 1991;266(19):2703.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

To I read with interest the recent article by Cady et al¹ entitled "Treatment of Acute Migraine With Subcutaneous Sumatriptan." The prospect of a new drug that is safe and effective for migraine headache treatment is exciting.

I did, however, note that 1.1% of patients at initial exposure to sumatriptan and 1.6% of patients who were given two consecutive doses of sumatriptan experienced nonspecified visual disturbances. Because the drug produces 5-HT^1D receptor-specific vasoconstriction of cranial arteries in humans, it is possible that this effect may extend to the arteries, perfusing the optic nerve and the retina.

Phelps and Corbett² and Drance et al³ have shown an increased incidence of low-tension glaucoma and an increased vasospastic arterial response in persons with migraine. The visual disturbances described after administration of sumatriptan could have resulted from relative ischemia secondary to posterior ciliary artery or central retinal . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?